Aileron therapeutics inc (ALRN)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Cash flows from operating activities:
Net loss

-6,748

-7,235

-7,749

-7,172

-7,213

-7,034

-7,434

-9,491

-7,588

-

-

-

-

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense

70

75

22

27

31

49

87

36

46

44

40

23

22

Net amortization of premiums and discounts on investments

30

61

76

60

34

69

91

49

44

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-4,557

Stock-based compensation expense

505

479

614

460

563

591

588

1,334

767

665

615

272

197

Change in deferred rent

-

-

-

-

-

-

-

-

-

0

0

4

7

Gain on sale of property and equipment

66

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-280

-665

900

-79

50

-198

456

-227

86

-145

618

-39

330

Other assets

-167

-

-

-

-533

-

-

-

-

-

-

-

-

Other assets

-

-

-

-

-

-

0

-4

-11

-114

26

-63

4

Accounts payable

-365

-880

628

847

-872

174

-22

-218

196

-8

267

329

-829

Operating lease liabilities

-104

-103

-94

-88

-85

-

-

-

-

-

-

-

-

Accrued expenses and other current liabilities

619

284

418

57

-374

-572

450

712

-231

131

833

696

-444

Net cash used in operating activities

-5,672

-6,305

-6,976

-5,692

-7,501

-6,663

-6,878

-7,456

-6,929

-

-

-

-

Cash flows from investing activities:
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-5,952

Purchases of property and equipment

-

15

5

4

127

1,932

2,278

206

7

68

27

9

38

Proceeds from sale of property and equipment

66

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of investments

-

-

-

-

-

4,963

5,468

13,215

7,548

18,926

43,383

1,482

7,265

Proceeds from sales or maturities of investments

10,992

7,506

6,968

2,000

8,100

15,200

9,150

26,000

9,955

-

-

-

-

Net cash provided by (used in) investing activities

11,058

4,764

3,737

-19,288

7,973

8,305

1,404

12,579

2,400

-

-

-

-

Cash flows from financing activities:
Proceeds from exercise of stock options

-

0

0

0

165

14

0

12

16

11

20

5

75

Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-7,303

Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs

-

-

-

-

-

-

-

-

-

0

-1

-22

494

Net cash provided by financing activities

-

-15

-51

23,865

165

1,277

1,210

12

16

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

569

Net decrease in cash, cash equivalents and restricted cash

5,386

-1,556

-3,290

-1,115

637

2,919

-4,264

5,135

-4,513

-1,565

4,031

1,368

-12,686

Supplemental disclosure of non-cash financing activities:
Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

0

0

21

20

Issuance costs for redeemable convertible preferred stock included in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

23

Deferred offering costs included in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-1,548

1,598

205